Physician profile
Peter R Ward
NPI 1831280973
$143.64
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.03 · 2020: $39.89 · 2021: $38.63 · 2022: $34.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.16 | 2021-2022 | |
| Genentech USA, INC. | $36.64 | 2019-2020 | |
| Tactile Systems Technology INC | $18.14 | 2020 | |
| Clovis Oncology, INC. | $16.14 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.64 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.